Latest Market Entry News

Pure Resources reaffirms exceptional metallurgical results at its Garnet Hills Project, achieving garnet grades up to 98% through sustainable processing. The company is now scaling up testing and forging strategic collaborations in the US to unlock downstream rare earth opportunities.

Cleo Diagnostics has launched a health economic study in partnership with EntityRisk and Norstella to support the U.S. market entry of its Ovarian Cancer Pre-Surgical Test, aiming to refine reimbursement strategies and accelerate commercialisation.

Audinate’s FY25 was a year of strategic transition marked by shipment of one million Dante devices, launch of a cloud-based management platform, and acquisition of Iris Studio to bolster AI-driven video capabilities. Despite revenue headwinds, the company is poised for growth in FY26 with strong gross profit momentum and a robust balance sheet.

AnteoTech has mutually terminated its A$1.4 million Queensland government grant to avoid costly co-investment, opting instead for cheaper third-party testing to advance its Ultranode™ battery technology.

Tetratherix has landed a $3.3 million Australian Government grant to co-fund a $7.4 million project expanding its synthetic polymer production and supporting its US market entry in 2026.

Archer Materials has partnered with Belgium’s IMEC to develop a scalable, cost-effective potassium ion biosensor using silicon semiconductor technology, aiming to accelerate commercial production by late 2025.

Audeara Limited has secured a five-year licensing agreement with Eastech (Huizhou) Co., Ltd. to bring its advanced hearing technology to China’s booming medical device market, leveraging major e-commerce platforms for distribution.

Linius Technologies has secured its first commercial contract for Captivate, a fan engagement platform that personalizes sports video experiences, with Honest Technology Partners. The deal guarantees over A$250,000 in revenue across two years, marking a significant milestone for Linius in the sports technology arena.

Neuren Pharmaceuticals reports a 16% rise in Q2 2025 royalties driven by Acadia’s DAYBUE sales growth and expanding patient base in the US. Full-year sales guidance remains strong with European market entry on the horizon.

EBR Systems has won final CMS approval for New Technology Add-On Payment reimbursement, paving the way for Medicare coverage of its innovative WiSE cardiac pacing system starting October 2025.

HeraMED advances AI-driven maternity care partnerships and strengthens its US commercial team, navigating policy uncertainties while progressing its global expansion and funding strategies.

Rhythm Biosciences has advanced its ColoSTAT® diagnostic kits to final production validation, demonstrating consistent detection of colorectal cancer across all stages in a pivotal study. The company is gearing up for regulatory submission and commercial launch later this year.